RAMELTEON

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21NO2
Molecular Weight	259.344
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=NCC[C@]1([H])CCc2ccc3c(CCO3)c21)O

InChI

InChIKey=YLXDSYKOBKBWJQ-LBPRGKRZSA-N

InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C16H21NO2
Molecular Weight	259.344
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Curator's Comment:: https://www.takeda.com/news/2011/20111007_3902.html

Ramelteon was approved by the United States (U.S.) in July 2005, and the Japanese Ministry of Health, Labour and Welfare in April 2010. It is currently available in the USA and Japan as ROZEREM and is indicated for the treatment of insomnia characterized by difficulty with sleep onset. In October 7, 2011, Takeda has decided to discontinue the development of ramelteon in Europe for the treatment of insomnia in order to best optimize Takeda’s resources for its research and development activities. Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT1 and MT2 receptors compared to the MT3 receptor. The activity of ramelteon at the MT1 and MT2 receptors is believed to contribute to its sleep-promoting properties since these receptors are acted upon by endogenous melatonin and are thought to be involved in the maintenance of the circadian rhythm underlying normal sleep-wake cycles. Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opiates.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Melatonin receptor 1 Target ID: CHEMBL2094268 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15494157	Agonist 2456	Insomnia

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 98 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Primary	Melatonin receptor	Approved 7997	ROZEREM Approved Use ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6-week studies (adults and elderly), and at the end of the 6-month study (adults and elderly) [see Clinical Studies (14) Launch Date 1121990400000

C_max

Value	Dose	Co-administered	Analyte	Population
25.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
36.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	Other AEs: Somnolence, Malaise... Other AEs: Somnolence (12.7%) Malaise (1.6%) Dizziness (3.2%) Nasopharyngitis (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
40 mg 1 times / day multiple, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22926624	unhealthy, 47 years Health Status: unhealthy Age Group: 47 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/22926624	Sources: https://pubmed.ncbi.nlm.nih.gov/22926624
8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Disc. AE: Somnolence, Dizziness... AEs leading to discontinuation/dose reduction: Somnolence (0.8%) Dizziness (0.5%) Nausea (0.3%) Fatigue (0.3%) Headache (0.3%) Insomnia (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
160 mg single, oral Highest studied dose Dose: 160 mg Route: oral Route: single Dose: 160 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unknown Health Status: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf

AEs

AE	Significance	Dose	Population
Malaise	1.6%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Somnolence	12.7%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Dizziness	3.2%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Nasopharyngitis	4.8%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Fatigue	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Headache	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Insomnia	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Nausea	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Dizziness	0.5% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Somnolence	0.8% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1470 inhibitor 1172 inducer 657	substrate 865 inducer 343	inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1268 CYP2C19 1215 P-gp 1089	CYP1A2 892 CYP2C 10 P-gp 1223	CYP1A2 618

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1406	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 28	no
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11	no
CYP2C9 1362	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11	no
CYP3A4 1462	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11	no
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11	no
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	no	no (co-administration study) Comment: theophylline AUC increased 40% and Cmax increased 35% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	no	no (co-administration study) Comment: dextromethorphan AUC and Cmax did not change Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 60, 63	no	no (co-administration study) Comment: ramelteon decreased digoxin exposure by 3% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 60, 63

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1223	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 60	inconclusive
CYP1A2 892	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	major	yes (co-administration study) Comment: fluvoxamine increased ramelteon AUC 190-fold and Cmax 70-fold; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2C 10	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	minor	yes (co-administration study) Comment: rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP3A4 1470	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	minor	yes (co-administration study) Comment: ketaconazole increased ramelteon AUC by 84% and Cmax 36%; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2C9 865	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 13	yes	yes (co-administration study) Comment: fluconazole increased AUC by 150% and Cmax by 150%; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 13

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_pharmr_CORRECTED_REVIEW.pdf Page: 53, 66

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY105591
1PlusChem LLC	1P0039D3
A2B Chem	AB51303
AA Blocks	AA0038TN
AChemBlock	M15422
AK Scientific	Q499
AOBIOUS INC	AOB87305
AbovChem LLC	HY-A0014
AlchemyPharm	AP00091
Angene	AGN-PC-0QOEYH
AstaTech	41159
BOC Sciences	196597-16-7
BOC Sciences	196597-17-8
BOC Sciences	196597-26-9
Bide Pharmatech	BD150225
BioSynth	J-502508
BlocksMatrix Scientific	125309
Capot Chemical	19120
Cayman Chemical	20389
Chem Scene	CS-M2669
ChemShuttle	151400
Compound Cloud	208902
Enamine	EN300-219936
Fluorochem	387715
Hairui	HR133856
Hangzhou APIChem Technology	AC-5275
Hangzhou Yuhao Chemical Technology	LL2545
Hangzhou Yuhao Chemical Technology	RT18941
HongKong Chemhere	SCF06046
HongKong Chemhere	SCF06047
KeyOrganics	AS-15740
KeyOrganics	CS-14200
Lab Network	LN01311915
Lab Network	LN01312113
Lab Seeker	SC-27438
Lan Pharmatech	LQT-B50166
MedChem Express	HY-A0014
MolPort	MolPort-003-666-751
MolPort	MolPort-006-395-839
Molcore	MC105591
Molnova	M13082
MuseChem	R006548
Nanjing Pope Bio-tech	NSTH-D40082
Norris Pharm	NSTH-D40082
Ryan Scientific	Exemestane
ShangHai Biochempartner	BCP001578
ShangHai Biochempartner	BCP18306
Sigma Aldrich	R-016
Sigma Aldrich	R-016\|CERILLIAN
Sigma Aldrich	SML2262
StruChem	SC-27438
Synthonix	15011
TargetMol	T1463
Tetrahedron	TS00255
Toronto Research Chemicals	R110051
ZINC	ZINC000003960338	http://zinc15.docking.org/substances/ZINC000003960338
eMolecules	23296366
eMolecules	300051179
eMolecules	5852446
eNovation Chemicals	D770000
mcule	MCULE-1886826647
mcule	MCULE-4134950887
mcule	MCULE-5218385358

PubMed

Title	Date	PubMed
Pharmacologic management of insomnia: past, present, and future.	2006 Dec	17118273
A new sleeping pill.	2006 Oct	17186577
Ramelteon for the treatment of insomnia.	2006 Oct	17157111
Ramelteon for insomnia in two youths with autistic disorder.	2006 Oct	17069551
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.	2006 Oct	17015817
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.	2006 Sep	16998419
Associated Professional Sleep Societies--SLEEP 2006 20th Anniversary Meeting. 17-22 June 2006, Salt Lake City, UT, USA.	2006 Sep	16952065
Treatment of sleep dysfunction and psychiatric disorders.	2006 Sep	16901376
Eszopiclone for late-life insomnia.	2007	18044182
Role of the melatonin system in the control of sleep: therapeutic implications.	2007	18020480
Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.	2007	17599165
[Melatonin, melatonin receptor agonists and tryptophan as sleep aids].	2007	17555058
Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?	2007	17447827
Putting insomnia to rest.	2007 Apr	17414828
Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.	2007 Apr	17410109
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.	2007 Apr	17389558
Putting "sleepdriving" and new safety warning in perspective.	2007 Aug	17712908
Treatment options for insomnia.	2007 Aug 15	17853625
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.	2007 Aug 15	17803013
Greater incidence of depression with hypnotic use than with placebo.	2007 Aug 21	17711589
[Recent and potential drugs for treatment of insomnia].	2007 Jan	17220574
New perspectives for the treatment of disorders of sleep and arousal.	2007 Jul	17652996
[New hypnotics: perspectives from sleep physiology].	2007 Jul-Aug	18265473
Hypnotic sedative drugs.	2007 Jun	17849930
The management of insomnia in the older adult.	2007 Jun	17633595
Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.	2007 Jun	17559740
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.	2007 May	17519067
In search of novel and therapeutically significant melatoninergic ligands.	2007 Nov	18221235
Gateways to clinical trials.	2007 Oct	18040531
Design and synthesis of new N1 and C3-substituted 4-fluoroindolic melatoninergics.	2007 Oct	17986002
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.	2007 Sep	17996657
Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.	2008	18673165
Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial.	2008	18423009
Melatonergic drugs in clinical practice.	2008	18368944
Efficacy and clinical safety of ramelteon: an evidence-based review.	2008 Aug	18603221
Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD.	2008 Aug	18060441
Pharmacotherapy for insomnia.	2008 Feb	18035234
[Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist].	2008 Jan	18187878
Jet lag: therapeutic use of melatonin and possible application of melatonin analogs.	2008 Jan-Mar	18342269
Ramelteon: a melatonin receptor agonist for the treatment of insomnia.	2008 Jan-Mar	18296808
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.	2008 Jul	18691991
Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.	2008 Jul 4	18501512
Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep?	2008 Sep	18844817
Sleep dysfunction in heart failure.	2008 Sep	18782505
Ramelteon: a novel approach in the treatment of insomnia.	2008 Sep	18648020
Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.	2008 Sep	18298466
Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.	2008 Sep 9	18664376
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.	2009	18609422
The effects of ramelteon in a first-night model of transient insomnia.	2009 Jan	18691937
The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease.	2009 Mar	18584227

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose 8 mg taken within 30 minutes of going to bed. It is recommended that drug not be taken with or immediately after a high fat meal.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:28:27 UTC 2021` Edited by `admin` on `Fri Jun 25 21:28:27 UTC 2021`
Record UNII	901AS54I69
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RAMELTEON

Official Name

English

RAMELTEON [JAN]

Common Name

English

RAMELTEON [VANDF]

Common Name

English

ROZEREM

Brand Name

English

TAK375

Code

English

(-)-N-(2-(((8S)-1,6,7,8-TETRAHYDRO-2H-INDENO(5,4-.BETA.)FURAN-8-YL)ETHYL)PROPANAMIDE

Common Name

English

RAMELTEON [HSDB]

Common Name

English

RAMELTEON [MART.]

Common Name

English

RAMELTEON [ORANGE BOOK]

Common Name

English

RAMELTEON [USAN]

Common Name

English

TAK-375

Code

English

RAMELTEON [WHO-DD]

Common Name

English

RAMELTEON [MI]

Common Name

English

PROPANAMIDE, N-(2-((8S)-1,6,7,8-TETRAHYDRO-2H-INDENO(5,4-.BETA.)FURAN-8-YL)ETHYL)-

Common Name

English

RAMELTEON [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N05CH02